Clinical Trials
49 trialsTGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
FluBuATG
Dartmouth-Hitchcock Medical Center
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
Herlev Hospital
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
MPN-RC 118 AVID200 in Myelofibrosis
Icahn School of Medicine at Mount Sinai
HaploOnly
University of Rochester
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Daiichi Sankyo
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Mayo Clinic
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
University of Pittsburgh
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
A Study in Myeloproliferative Disorders
Eli Lilly and Company
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
Eli Lilly and Company
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Prescient Therapeutics, Ltd.
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
JW Pharmaceutical
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Indiana University
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Millennium Pharmaceuticals, Inc.
Pyroxamide in Treating Patients With Advanced Cancer
Memorial Sloan Kettering Cancer Center
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
National Cancer Institute (NCI)
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
National Cancer Institute (NCI)
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
FTS Study in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy in Treating Patients With Advanced Cancer
NYU Langone Health
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
Case Comprehensive Cancer Center
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
University of Arizona
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
CASI pharmaceuticals, Inc.